Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. Juni 2019 08:00 ET | Quelle: BeyondSpring, Inc.

BeyondSpring Set to Join FTSE Russell 3000® Index

NEW YORK, June 20, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that it will join...
26. Februar 2019 07:30 ET | Quelle: BeyondSpring, Inc.

New Data Shows Addition of BeyondSpring’s Plinabulin Reverses Neulasta’s Potential Immune-Suppressive Phenotype in Treating Chemotherapy-Induced Neutropenia

BeyondSpring to Present Results at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium NEW YORK, Feb. 26, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical...
26. Januar 2018 08:00 ET | Quelle: BeyondSpring, Inc.

BeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Plinabulin and Neulasta have Very Similar Grade 4 Neutropenia Incidence and Duration of Severe Neutropenia (DSN) in the Phase 2 Portion of Phase 2/3 Trial Study 105 with Docetaxel-Induced Neutropenia ...
14. Dezember 2017 08:00 ET | Quelle: BeyondSpring, Inc.

BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia (CIN)

NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
04. Dezember 2017 07:00 ET | Quelle: BeyondSpring, Inc.

BeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in China

NEW YORK, Dec. 04, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
30. November 2017 09:58 ET | Quelle: BeyondSpring, Inc.

BeyondSpring Initiates Global Phase 2/3 Trial with Plinabulin in China for the Prevention of Chemotherapy-Induced Neutropenia to Demonstrate Superiority

NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
26. Oktober 2017 08:30 ET | Quelle: BeyondSpring, Inc.

BeyondSpring Announces the First Patient Enrolled in China in its Global Phase 2/3 Trial with Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia

NEW YORK, Oct. 26, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
23. Oktober 2017 08:30 ET | Quelle: BeyondSpring, Inc.

BeyondSpring Receives Two Grants in China to Further Develop Innovative Drug Pipeline

NEW YORK, Oct. 23, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
18. Oktober 2017 08:30 ET | Quelle: BeyondSpring, Inc.

BeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San Francisco

NEW YORK, Oct. 18, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...
06. Juli 2017 08:00 ET | Quelle: BeyondSpring, Inc.

China FDA Approves CTAs for BeyondSpring’s Second Global Plinabulin Registrational Trial for Chemotherapy-Induced Neutropenia Prevention

NEW YORK, July 06, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer...

Nächste Seite